Cargando…

Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer

Nivolumab, a human monoclonal antibody against programmed death‐1, is approved for the treatment of non–small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but potentially fatal immune‐related adverse event. Currently,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sata, Masafumi, Sasaki, Shinichi, Oikado, Katsunori, Saito, Yoshinobu, Tominaga, Junya, Sakai, Fumikazu, Kato, Terufumi, Iwasawa, Tae, Kenmotsu, Hirotsugu, Kusumoto, Masahiko, Baba, Tomohisa, Endo, Masahiro, Fujiwara, Yutaka, Sugiura, Hiroaki, Yanagawa, Noriyo, Ito, Yoshihiko, Sakamoto, Takahiko, Ohe, Yuichiro, Kuwano, Kazuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019226/ https://www.ncbi.nlm.nih.gov/pubmed/33125784 http://dx.doi.org/10.1111/cas.14715

Ejemplares similares

Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non–small cell lung cancer
por: Saito, Yoshinobu, et al.
Publicado: (2021)

Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
por: Baba, Tomohisa, et al.
Publicado: (2023)

Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy
por: Noda‐Narita, Shoko, et al.
Publicado: (2022)

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan
por: Ohe, Yuichiro, et al.
Publicado: (2020)

Prognostic Factors in Interstitial Lung Disease Associated with Primary Sjögren’s Syndrome: A Retrospective Analysis of 33 Pathologically–Proven Cases
por: Enomoto, Yasunori, et al.
Publicado: (2013)

Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
por: Ikeda, Satoshi, et al.
Publicado: (2021)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2020)

A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Imaging Diagnosis of Interstitial Pneumonia with Emphysema (Combined Pulmonary Fibrosis and Emphysema)
por: Sakai, Fumikazu, et al.
Publicado: (2012)

Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2019)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2021)

Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
por: Yamakawa, Hideaki, et al.
Publicado: (2018)

Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer
por: Gemma, Akihiko, et al.
Publicado: (2014)

Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report
por: Honjo, Osamu, et al.
Publicado: (2019)

Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)
por: Yamakawa, Hideaki, et al.
Publicado: (2021)

Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Retrospective analysis of long‐term survival factors in patients with advanced non‐small cell lung cancer treated with nivolumab
por: Murakami, Yusuke, et al.
Publicado: (2022)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
por: Yamamoto, Noboru, et al.
Publicado: (2018)

Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
por: Gannichida, Ako, et al.
Publicado: (2022)

Prognostic Stratification According to Size and Dominance of Radiologic Solid Component in Clinical Stage IA Lung Adenocarcinoma
por: Nakao, Masayuki, et al.
Publicado: (2022)

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review
por: Yamakawa, Hideaki, et al.
Publicado: (2022)

Quantitative Analysis for Lung Disease on Thin-Section CT
por: Iwasawa, Tae, et al.
Publicado: (2023)

Association between chronic bacterial airway infection and prognosis of bronchiolitis obliterans syndrome after hematopoietic cell transplantation
por: Yomota, Makiko, et al.
Publicado: (2019)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Concordance between transbronchial lung cryobiopsy and surgical lung biopsy for interstitial lung disease in the same patients
por: Baba, Tomohisa, et al.
Publicado: (2023)

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
por: Kudo, Fumiaki, et al.
Publicado: (2018)

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab
por: Takahashi, Ayumu, et al.
Publicado: (2018)

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
por: Kawashima, Yosuke, et al.
Publicado: (2019)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

RNAi Therapeutic Platforms for Lung Diseases
por: Fujita, Yu, et al.
Publicado: (2013)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
por: Mamesaya, Nobuaki, et al.
Publicado: (2016)

Development of Small RNA Delivery Systems for Lung Cancer Therapy
por: Fujita, Yu, et al.
Publicado: (2015)

Rapid Deterioration of Unilateral Upper Lung-field Pulmonary Fibrosis
por: Yamakawa, Hideaki, et al.
Publicado: (2022)

Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2022)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Case series of pleomorphic carcinomas of the lung treated with nivolumab
por: Kanazu, Masaki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fl5egpc483e94p3u5s5cnhultf